Despite its clinical efficacy, ICB is limited by the emergence of MHC-deficient and IFN-unresponsive tumour cell clones that escape recognition and destruction by CD8+ cytolytic T cells4,5. This evidence concerns the gene IFNA1 and neoplasm.